1386P 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)
Avitia, J.W., Bailen, J.L., Shore, N.D., Tutrone, R.F., Nordquist, L.T., Walling, J., Peterson, L., Schotzinger, R., Moore, W.R.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1777P Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
De Giorgi, U.F.F., Freedland, S.J., Gleave, M.E., Tutrone, R., Bailen, J.L., Roos, E., Kliment, J., Marx, G.M., Karsh, L.I., Ramirez-Backhaus, M., Uchio, E., Supiot, S., Tang, Y., Rosbrook, B., Haas, G.P., Rosales, M., Zohren, F., Shore, N.D.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
Sustained castration to < 20 ng/dl for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study
Tombal, B., Shore, N.D., George, D.J., Cookson, M.S., Saltzstein, D.R., Mehlhaff, B., Tutrone, R., Bailen, J.L., Brown, B., Lu, S., Schulmann, T., Hanson, S., Saad, F.
Published in European urology (01.02.2022)
Published in European urology (01.02.2022)
Get full text
Journal Article
Testosterone recovery for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study
Tombal, B., Tutrone, R.F., Saad, F., George, D.J., Bailen, J.L., Cookson, M.S., Saltzstein, D.R., Brown, B., Lu, S., Shore, N.D.
Published in European urology open science (Online) (01.11.2022)
Published in European urology open science (Online) (01.11.2022)
Get full text
Journal Article
Oral relugolix for androgen deprivation therapy in advanced prostate cancer: Detailed safety analysis from the randomized phase 3 HERO study
Tombal, B., Mehlhaff, B., Shore, N.D., George, D.J., Cookson, M.S., Saltzstein, D.R., Tutrone, R.F., Bailen, J.L, Brown, B., Langenberg, A.G.M., Lu, S., Fallick, M., Hanson, S., Saad, F.
Published in European urology open science (Online) (01.11.2022)
Published in European urology open science (Online) (01.11.2022)
Get full text
Journal Article
Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)
Dearnaley, D., Saltzstein, D.R., Sylvester, J.E., Karsh, L., Mehlhaff, B.A., Pieczonka, C., Bailen, J.L., Maclean, D.B., Sankoh, S., Faessel, H.M., Lin, H.M., Shore, N.D.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
P4575Comparison of thromboembolic and bleeding risk scores in direct oral anticoagulant naive patients with non-valvular atrial fibrillation
Elvira-Ruiz, G., Caro-Martinez, C., Andreu-Cayuelas, J.M., Flores-Blanco, P.J., Albendin-Iglesias, H., Gomez-Molina, M., Lopez-Cuenca, A., Cambronero-Sanchez, F., Rodriguez-Serrano, A.I., Leithold, B.G., Sanchez-Galian, M.J., Guerrero-Perez, E., Bailen-Lorenzo, J.L., Valdes-Chavarri, M., Manzano Fernandez, S.
Published in European heart journal (01.08.2017)
Published in European heart journal (01.08.2017)
Get full text
Journal Article